ReviewCurrent psychiatry reports2016
Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.
Review in Current psychiatry reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Integrative Transcriptomic and Interactome Analyses Prioritize Candidate Genes for Alzheimer's Disease.Molecular neurobiology · 2026Article
- A new hope: locus coeruleus-norepinephrine system at the nexus of neuropsychiatric symptoms.Molecular psychiatry · 2026Review
- Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Adult-onset hippocampal α7 nicotinic acetylcholine receptor loss rapidly drives Alzheimer-like neuropathology in mice.Frontiers in pharmacology · 2026Article
- The delta-opioid receptor: a therapeutic target for Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- Network-level organization of systemic inflammation reflects early Alzheimer's-like behavioral changes.Scientific reports · 2025Article
- Agitation in Alzheimer's disease: From assessment to therapeutics.World journal of psychiatry · 2025Review
- Network-Level Organization of Systemic Inflammation Reflects Early Alzheimer's-Like Behavioral Changes.Research square · 2025Article
- Brexpiprazole for agitation in alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials.Indian journal of psychiatry · 2025Review
- Usability of Behavioural Recording Application (BRA) for Coping With Behavioural and Psychological Symptoms of Dementia.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2025Article
- Establishing the Foundations of Emotional Intelligence in Care Companion Robots to Mitigate Agitation Among High-Risk Patients With Dementia: Protocol for an Empathetic Patient-Robot Interaction Study.JMIR research protocols · 2024Article
- In a circuit necessary for cognition and emotional affect, Alzheimer's-like pathology associates with neuroinflammation, cognitive and motivational deficits in the young adult TgF344-AD rat.Brain, behavior, & immunity - health · 2024Article
- Evaluation of the Neuroprotective Effect of Organic Selenium Compounds: An in Vitro Model of Alzheimer's Disease.Biological trace element research · 2024Article
- Barriers and facilitators to care for agitation and/or aggression among persons living with dementia in long-term care.BMC geriatrics · 2024Article
- Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia.Journal of health economics and outcomes research · 2024Article
- The Effect of Adding Mirtazapine to Quetiapine on Reducing Agitation in Patients with Alzheimer's Disease.Journal of Alzheimer's disease reports · 2024Article
- Diethyl butylmalonate attenuates cognitive deficits and depression in 5×FAD mice.Frontiers in neuroscience · 2024Article
- The neural basis of neuropsychiatric symptoms in Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- Care partner evaluation of the behaviors in the Cohen-Mansfield Agitation Inventory.Frontiers in dementia · 2024Article
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
More than five million Americans suffer from Alzheimer's disease (AD), and this number is expected to triple by 2050. While impairments in cognition, particularly memory, are typically the defining features of the clinical syndrome, behavioral symptoms are extremely common, affecting up to 90% of patients. Behavioral symptoms in AD can be difficult to manage and may require a combination of non-pharmacological and pharmacological approaches. The latter is complicated by FDA "black-box warnings" for the medication classes most often used to target these symptoms, and currently there are initiatives in place to limit their use. In this review, we describe common behavioral symptoms of AD-with a particular focus on the challenging symptoms of "agitation" and "irritability"-and discuss evidence-based approaches to their management. Ultimately, multidimensional approaches must be tailored to the patient and their environment, though evidence-based practices should define the treatment of agitation and irritability in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.